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Background: The long-term outcomes for endovascular intervention (EVI) in Asian
people with critical limb ischemia (CLI) are still uncertain. This study was designed to
assess the feasibility and patient outcomes after EVI for Taiwanese patients with CLI.
Methods: From June 2005 to December 2011, 270 patients underwent EVI for CLI of
333 limbs. Primary patency (PP), assisted primary patency (AP), limb salvage, sustained
clinical success (SCS), secondary sustained clinical success (SSCS) and survival were
assessed using Kaplan-Meier analysis.
Results: The procedural success rate was 94% and 53% of legs required stent
implantation to optimize the procedural result. The periprocedural mortality and major
complications rate within 30 days was 0.6% and 6.9%, respectively. During the mean
follow-up time of 2720 months (1-77), 64 patients died and 25 legs underwent major
amputation with a total of 93% follow-up rate. 81% of patients with tissue loss had wound
healing at 6 months and 75% of patients can be ambulatory with or without assist device
at 1 year. Overall survival rate of CLI patients at 1, 3, 5 year was 88%, 70% and 61%. The
rates of free from major and any amputation at 1 year were 90% and 78%, respectively
and can be maintained to 5 years. The PP and AP at 1, 3, 5 year was 58%, 37%, 31% and
79%, 61% and 52%, respectively. The SCS and SSCS were 65%, 46%, 38% and 80%,
64%, 55% at 1, 3,5 years, respectively.
Conclusions: EVI proved to be a safe and feasible procedure for CLI patients. Sustained
limb salvage and clinical success can be achieved with an active surveillance program and
prompt assisted intervention during long-term follow-up.
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Background: Body surface area (BSA) is a good indicator of overall metabolic mass.
We investigated whether BSA affects clinical outcome in patients with lower extremity
peripheral arterial disease (LEPAD).
Methods: We reviewed records for 365 patients with new diagnosis of LEPAD from
2001 to 2007. Patients were followed for a mean of 62  43 months. Patients with
stenosis of 70% or more were included. Each diseased leg was considered 1 case for a
total of 602 cases. We calculated BSA in meters squared using Mosteller formula. Based
on BSA, cases were divided into three groups: low (1.2BSA1.72), normal
(1.72BSA2) and high (2BSA3). Primary endpoint was time to all-cause mortality;
secondary endpoints were time to amputation and time to revascularization.
Results: Increased BSA demonstrated an inverse linear relationship with mortality
(Graph), even after adjusting for age, body mass index, sex, diabetes, hypertension,
coronary artery disease and medications. Stratified analysis confirmed this effect (Table).
High BSA was also associated with a longer time-to-amputation rate in contrast to normal
and low BSA (hazard ratio 0.54, 95% confidence interval 0.24-1.18, p0.012).
Conclusions: High BSA reduces risk of all-cause mortality and lengthens time to
amputation in patients with lower extremity peripheral arterial disease.
Subgroup All-Cause Mortality Analysis by Multivariate Cox Regression
Subgroup
BSA:
1.2–1.72
(n109)
BSA: 1.72–2
(n129)
BSA: 2–3
(n127)
BMI  30 Mortality (n) 36 30 8
HR (95% CI) 0.60 (0.29–1.24) 0.17 (0.06–0.52)
P value 0.17 0.002
BMI  30 Mortality (n) 3 6 14
HR (95% CI) 1.08 (0.01–11.4) 2.8 (0.00–18.20)
P value 0.98 0.60
Female Mortality (n) 24 15 4
HR (95% CI) 0.78 (0.21–2.85) 0.18 (0.03–1.27)
P value 0.71 0.08
Male Mortality (n) 15 21 18
HR (95% CI) 0.62 (0.23–1.67) 0.28 (0.08–0.90)
P value 0.34 0.03
Age  75 Mortality (n) 20 19 17
HR (95% CI) 0.35 (0.15–0.82) 0.19 (0.06–0.54)
P value 0.016 0.002
Age  75 Mortality (n) 19 17 5
HR (95% CI) 2.69 (0.71–10.23) 0.43 (0.08–2.35)
P value 0.14 0.33
Suprainguinal Mortality (n) 8 2 0
HR (95% CI) 1.10 (0.00–40.6) 0 (0–10.4)
P value 0.078 0.99
Infrainguinal Mortality (n) 26 27 14
HR (95% CI) 0.77 (0.34–1.74) 0.17 (0.06–0.47)
P value 0.54 0.001
Hazard ratio when compared to the subgroup BSA 1.2-1.72, according to the
Mosteller formula.
BMI, body mass index; BSA, body surface area; CI, confidence interval; HR,
hazard ratio.
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Background: Renal Artery Aneurysms (RAAs) can be surgically treated but due to high
risk, endovascular procedures have been proposed (coils, graft...). All these techniques
have some drawbacks, potential complications and contraindications. We propose a new
technique: the Multilayer Flow Modulator (MFM*), a self expandable stent and we report
8 cases.
Methods: This MFM* is a 3D braided tube made of several interconnected layers
without any covering. Our earliest tests, in vitro (theorical simulation computerized Fluid
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